



Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Fireside Chat Date and Time: Thursday December 4, 2025, at 9:10 a.m. EST

- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast [here](#)
- Management will also participate in one-on-one meetings

A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website, www.foghornrx.com, and will be available for 30 days.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghornrx.com for more information on the Company, and follow us on [X](#) and [LinkedIn](#).

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghornrx.com